Cargando…
Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation
Background: Heparin-induced thrombocytopenia (HIT) is a serious, immune-mediated adverse drug reaction to unfractionated heparin (UFH) affecting also patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). Although the association between VA-ECMO support and the development o...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821297/ https://www.ncbi.nlm.nih.gov/pubmed/36615162 http://dx.doi.org/10.3390/jcm12010362 |
_version_ | 1784865663573032960 |
---|---|
author | Lüsebrink, Enzo Scherer, Clemens Binzenhöfer, Leonhard Hoffmann, Sabine Höpler, Julia Kellnar, Antonia Thienel, Manuela Joskowiak, Dominik Peterß, Sven Petzold, Tobias Deseive, Simon Hein, Ralph Brunner, Stefan Kääb, Stefan Braun, Daniel Theiss, Hans Hausleiter, Jörg Hagl, Christian Massberg, Steffen Orban, Martin |
author_facet | Lüsebrink, Enzo Scherer, Clemens Binzenhöfer, Leonhard Hoffmann, Sabine Höpler, Julia Kellnar, Antonia Thienel, Manuela Joskowiak, Dominik Peterß, Sven Petzold, Tobias Deseive, Simon Hein, Ralph Brunner, Stefan Kääb, Stefan Braun, Daniel Theiss, Hans Hausleiter, Jörg Hagl, Christian Massberg, Steffen Orban, Martin |
author_sort | Lüsebrink, Enzo |
collection | PubMed |
description | Background: Heparin-induced thrombocytopenia (HIT) is a serious, immune-mediated adverse drug reaction to unfractionated heparin (UFH) affecting also patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). Although the association between VA-ECMO support and the development of thrombocytopenia has long been known and discussed, HIT as one underlying cause is still insufficiently understood. Therefore, the purpose of this study was to further investigate the epidemiology, mortality, diagnosis, and clinical management of HIT occurring in VA-ECMO patients treated with UFH. Methods: We conducted a retrospective single-center study including adult patients (≥18 years) with VA-ECMO support in the cardiac intensive care unit (ICU) of the University Hospital of Munich (LMU) between January 2013 and May 2022, excluding patients with a known history of HIT upon admission. Differences in baseline characteristics and clinical outcome between excluded HIT (positive anti-platelet factor 4 (PF4)/heparin antibody test but negative functional assay) and confirmed HIT (positive anti-PF4/heparin antibody test and positive functional assay) VA-ECMO patients as well as diagnosis and clinical management of HIT were analysed. Results: Among the 373 patients included, anti-PF4/heparin antibodies were detected in 53/373 (14.2%) patients. Functional HIT testing confirmed HIT in 13 cases (3.5%) and excluded HIT in 40 cases (10.7%), corresponding to a prevalence of confirmed HIT of 13/373 (3.5%) [1.6, 5.3] and a positive predictive value (PPV) of 24.5% for the antibody screening test. The platelet course including platelet recovery following argatroban initiation was similar between all groups. One-month mortality in patients with excluded HIT was 14/40 (35%) and 3-month mortality 17/40 (43%), compared to 5/13 (38%) (p > 0.999), and 6/13 (46%) (p > 0.999) in patients with confirmed HIT. Neurological outcome in both groups measured by the cerebral performance category of survivors on hospital discharge was similar, as well as adverse events during VA-ECMO therapy. Conclusions: With a prevalence of 3.5%, HIT is a non-frequent complication in patients on VA-ECMO and was not associated with a higher mortality rate. HIT was ultimately excluded by functional essay in 75% of VA-ECMO patients with clinical suspicion of HIT and positive anti-PF4/heparin antibody test. Argatroban seems to be an appropriate and safe therapeutic option for confirmed HIT-positive patients on VA-ECMO support. |
format | Online Article Text |
id | pubmed-9821297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98212972023-01-07 Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation Lüsebrink, Enzo Scherer, Clemens Binzenhöfer, Leonhard Hoffmann, Sabine Höpler, Julia Kellnar, Antonia Thienel, Manuela Joskowiak, Dominik Peterß, Sven Petzold, Tobias Deseive, Simon Hein, Ralph Brunner, Stefan Kääb, Stefan Braun, Daniel Theiss, Hans Hausleiter, Jörg Hagl, Christian Massberg, Steffen Orban, Martin J Clin Med Article Background: Heparin-induced thrombocytopenia (HIT) is a serious, immune-mediated adverse drug reaction to unfractionated heparin (UFH) affecting also patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). Although the association between VA-ECMO support and the development of thrombocytopenia has long been known and discussed, HIT as one underlying cause is still insufficiently understood. Therefore, the purpose of this study was to further investigate the epidemiology, mortality, diagnosis, and clinical management of HIT occurring in VA-ECMO patients treated with UFH. Methods: We conducted a retrospective single-center study including adult patients (≥18 years) with VA-ECMO support in the cardiac intensive care unit (ICU) of the University Hospital of Munich (LMU) between January 2013 and May 2022, excluding patients with a known history of HIT upon admission. Differences in baseline characteristics and clinical outcome between excluded HIT (positive anti-platelet factor 4 (PF4)/heparin antibody test but negative functional assay) and confirmed HIT (positive anti-PF4/heparin antibody test and positive functional assay) VA-ECMO patients as well as diagnosis and clinical management of HIT were analysed. Results: Among the 373 patients included, anti-PF4/heparin antibodies were detected in 53/373 (14.2%) patients. Functional HIT testing confirmed HIT in 13 cases (3.5%) and excluded HIT in 40 cases (10.7%), corresponding to a prevalence of confirmed HIT of 13/373 (3.5%) [1.6, 5.3] and a positive predictive value (PPV) of 24.5% for the antibody screening test. The platelet course including platelet recovery following argatroban initiation was similar between all groups. One-month mortality in patients with excluded HIT was 14/40 (35%) and 3-month mortality 17/40 (43%), compared to 5/13 (38%) (p > 0.999), and 6/13 (46%) (p > 0.999) in patients with confirmed HIT. Neurological outcome in both groups measured by the cerebral performance category of survivors on hospital discharge was similar, as well as adverse events during VA-ECMO therapy. Conclusions: With a prevalence of 3.5%, HIT is a non-frequent complication in patients on VA-ECMO and was not associated with a higher mortality rate. HIT was ultimately excluded by functional essay in 75% of VA-ECMO patients with clinical suspicion of HIT and positive anti-PF4/heparin antibody test. Argatroban seems to be an appropriate and safe therapeutic option for confirmed HIT-positive patients on VA-ECMO support. MDPI 2023-01-02 /pmc/articles/PMC9821297/ /pubmed/36615162 http://dx.doi.org/10.3390/jcm12010362 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lüsebrink, Enzo Scherer, Clemens Binzenhöfer, Leonhard Hoffmann, Sabine Höpler, Julia Kellnar, Antonia Thienel, Manuela Joskowiak, Dominik Peterß, Sven Petzold, Tobias Deseive, Simon Hein, Ralph Brunner, Stefan Kääb, Stefan Braun, Daniel Theiss, Hans Hausleiter, Jörg Hagl, Christian Massberg, Steffen Orban, Martin Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title | Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title_full | Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title_fullStr | Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title_full_unstemmed | Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title_short | Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation |
title_sort | heparin-induced thrombocytopenia in patients undergoing venoarterial extracorporeal membrane oxygenation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821297/ https://www.ncbi.nlm.nih.gov/pubmed/36615162 http://dx.doi.org/10.3390/jcm12010362 |
work_keys_str_mv | AT lusebrinkenzo heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT schererclemens heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT binzenhoferleonhard heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT hoffmannsabine heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT hoplerjulia heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT kellnarantonia heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT thienelmanuela heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT joskowiakdominik heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT peterßsven heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT petzoldtobias heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT deseivesimon heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT heinralph heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT brunnerstefan heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT kaabstefan heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT braundaniel heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT theisshans heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT hausleiterjorg heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT haglchristian heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT massbergsteffen heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation AT orbanmartin heparininducedthrombocytopeniainpatientsundergoingvenoarterialextracorporealmembraneoxygenation |